Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

Definium Therapeutics Inc. (DFTX) — NEW YORK, August 26, 2026--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events:

Source: Business Wire — read the full announcement there.

Browse more sector announcements in our press release archive.